Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer
Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Ralf‐Dieter Hofheinz(University of Mannheim), Gerald Illerhaus(Klinikum Stuttgart), Dirk Arnold(Asklepios Klinik Altona), Stefan Post(University of Mannheim), Uwe M. Martens(Memorial Sloan Kettering Cancer Center), Stephan Probst(Klinikum Bielefeld), Ulrich Ronellenfitsch(University of Mannheim), Kersten Grimm(Krankenhaus Nordwest), Stefan Mönig(Hôpital Beau-Séjour), Frank Mayer(Institute for Sports Medicine), Markus Moehler(Johannes Gutenberg University Mainz), Wolf O. Bechstein(Unknown), Nicole Prasnikar(Asklepios Klinik Barmbek), Jan Stoehlmacher(University of Southern California), Helmut Messmann(University Hospital Augsburg), Kim Barbara Luley(University Hospital Schleswig-Holstein), Elke Jäger(Krankenhaus Nordwest), Harald Schmalenberg(Heidelberg University), Matthias Egger(Ortenau Klinikum), Stefan Berkhoff(Krankenhaus Nordwest), Michael Koenigsmann, Wolfgang Fischbach(Klinikum Aschaffenburg), Jörg T. Hartmann(University of Tübingen), Thomas Kraus(Krankenhaus Nordwest), Claudia Pauligk(Goethe University Frankfurt), Heinz‐Gert Höffkes(Klinikum Fulda), Nils Homann(Fraunhofer Project Centre Wolfsburg)
Cited by 473
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
|New England Journal of Medicine|2021|1.7k